A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria
- 1 July 2014
- journal article
- research article
- Published by Elsevier BV in Epilepsy Research
- Vol. 108 (5), 986-988
- https://doi.org/10.1016/j.eplepsyres.2014.03.015
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studiesEpilepsia, 2013
- Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders?Current Opinion in Neurology, 2013
- Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonistActa Neurologica Scandinavica, 2013
- Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307Epilepsia, 2012
- Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305Epilepsia, 2012
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Randomized phase III study 306Neurology, 2012
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- Strategy for utilization of new antiepileptic drugsCurrent Opinion in Neurology, 2008